AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,012.00
+97.50 (2.49%)
Real-time:   3:29PM GMT
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 3,801.72 - 4,014.50
52 week 3,746.00 - 4,931.68
Open 3,957.50
Vol / Avg. 2.40M/2.60M
Mkt cap 50.96B*
P/E 25.93
Div/yield 131.00/4.70*
EPS 1.55*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Apr 29, 2016
AstraZeneca PLC Annual Shareholders Meeting Add to calendar
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Release Add to calendar
Mar 1, 2016
AstraZeneca PLC at Credit Suisse One-on-One Healthcare Conference Add to calendar
Feb 29, 2016
AstraZeneca PLC at Daiwa Investment Conference Add to calendar
Feb 10, 2016
AstraZeneca PLC at Leerink Partners Global Healthcare Conference
Feb 8, 2016
AstraZeneca PLC Investor Roadshow-Europe, North America
Feb 4, 2016
Full Year 2015 AstraZeneca PLC Earnings Call
Feb 4, 2016
Full Year 2015 AstraZeneca PLC Earnings Release
Jan 13, 2016
AstraZeneca PLC at JPMorgan Healthcare Conference
Dec 17, 2015
AstraZeneca PLC Conference Call to Discuss Majority Stake Investment in Acerta Pharma
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.63% 11.44%
Operating margin 17.00% 16.65%
EBITD margin - 32.38%
Return on average assets 5.67% 4.76%
Return on average equity 18.09% 14.82%
Employees 57,500 -
CDP Score - 93 A

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, GPPS
Menelas Pangalos Executive Vice President - Innovative Medicines